Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Filed Chapter 11
ABLE LABORATORIES INC (ABRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/21/2006 8-K Quarterly results
03/06/2006 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Able Laboratories, Inc. Files Proposed Plan of Reorganization and Disclosure Statement",
"Plan of Reorganization",
"Disclosure Statement"
11/17/2005 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Asset Purchase Agreement between the Company and Sun Pharmaceutical Industries Limited",
"Able Laboratories, Inc. Holds Auction for Its Assets",
"Order Authorizing Sale of Certain Assets"
10/25/2005 8-K Acquisition/merger/asset purchase announced
Docs: "Asset Purchase Agreement between the Company and Aurobindo"
08/17/2005 8-K Other Events, Financial Statements and Exhibits
Docs: "Item 8.01 Other Events.",
"Able Laboratories, Inc. to Sell Business in Light of FDA Requirements for Relaunch of Products"
07/22/2005 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Able Laboratories, Inc. Receives Notice of Delisting from The Nasdaq Stock Market"
07/20/2005 8-K Filed for Chapter 11
Docs: "On July 18, 2005, Able Laboratories, Inc.",
"Able Laboratories, Inc. Files for Voluntary Chapter 11 Reorganization"
07/15/2005 8-K Entry into a Material Definitive Agreement
07/08/2005 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Able Laboratories, Inc. Announces Resignation of President Cranbury, NJ, July 7, 2005 - Able Laboratories, Inc. today announced that Robert G. Mauro, the Company's President and interim Chief Executive Officer and a director, has tendered his resignation and the Company has accepted his resignation from each of those positions. The Company is presently seeking an appropriate replacement to lead the Company in addressing the Company's previously disclosed regulatory issues, including its recall of all products and its suspension of all manufacturing operations. Meanwhile, day-to-day activities are expected to continue to be overseen by the board of directors and carried out by the Company's senior management team and its retained consultants. The ongoing disruption in the Company's operatio...",
"Able Laboratories, Inc. Cancels Annual Stockholder Meeting Cranbury, NJ, June 30, 2005 - Able Laboratories, Inc. announced today that it is canceling the annual meeting of stockholders scheduled to take place on July 8, 2005. At this time, the Company, its management team and its retained consultants are continuing to focus the Company's resources on addressing the Company's previously disclosed regulatory issues, including its recall of all products and its suspension of all manufacturing operations. The ongoing disruption in the Company's operations caused by the recall and the suspension of manufacturing activities has had, and will continue to have, a material adverse effect on the Company's results of operations and financial position. Able can give no assurance as to if or when it wi..."
06/15/2005 8-K Other Events, Financial Statements and Exhibits
Docs: "Able Laboratories, Inc. Workforce Reduction Cranbury, NJ, June 9, 2005 - Able Laboratories, Inc. announced today that it is making further staff reductions. Able anticipates making further reductions in staff in order to conserve assets and assist it in retaining key employees as it continues to address pending regulatory issues, evaluates its strategic alternatives and formulates and executes its plan for future operations. As the Company previously announced, the disruption in its operations and reduction in its workforce is expected to have a material adverse effect on its results of operations and financial position. At this time, the Company can give no assurance as to when it will be able to resume manufacturing operations. Further information on Able may be found on the Company's we...",
"Able Laboratories, Inc. Announces New Annual Meeting Date Cranbury, NJ, June 10, 2005 - Able Laboratories, Inc. announced today that it will postpone its scheduled 2005 annual meeting of stockholders to a later time and place. The adjournment of the meeting will be held at the offices of Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210, at 9:00 a.m. on July 8, 2005. Able decided to adjourn the meeting to a later date in order to permit further communications with stockholders prior to the meeting and to enable management to continue to focus on the Company's ongoing efforts to address current operating issues as announced in Able's recent press releases. Further information on Able may be found on the Company's web site, www.ablelabs.com."
06/07/2005 8-K Other Events, Financial Statements and Exhibits
Docs: "Able Laboratories, Inc. Announces Workforce Reduction"
05/27/2005 8-K Other Events, Financial Statements and Exhibits
Docs: "ABLE LABORATORIES, INC. SUSPENDS MANUFACTURING OPERATIONS, ANNOUNCES PRODUCT RECALL"
05/25/2005 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
Docs: "Able Laboratories, Inc. Announces Resignation of Chairman and Chief Executive Officer",
"Able Laboratories, Inc. Updates Status of Internal Review, Withdraws Guidance"
05/12/2005 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Investor Contact:"
05/03/2005 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Compensation Plan for Non-Employee Directors"
03/10/2005 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Able Laboratories Reports Financial Results for 2004 Fourth Quarter and Full Year Net Sales Increase 38% to $31.4 Million for Q4 2004 from $22.8 Million for Q4 2003 Net Sales Increase 33% to $103.2 Million for 2004 from $77.6 Million for 2003 Diluted Earnings per Share Increases 146% to $0.32 for Q4 2004 from $0.13 for Q4 2003 Diluted Earnings per Share Increases 63% to $0.75 for 2004 from $0.46 for 2003"
01/03/2005 8-K Entry into a Material Definitive Agreement
12/01/2004 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Able Laboratories Announces Senior Management Changes"
11/03/2004 8-K Quarterly results
Docs: "ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.",
"Able Laboratories Reports Third Quarter 2004 Results"
09/13/2004 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "ITEM 1.01 ENTRY INTO A DEFINITIVE MATERIAL AGREEMENT",
"AGREEMENT WITH JOAN JANULIS",
"AGREEMENT WITH JANET E. PENNER"
07/28/2004 8-K Quarterly results
Docs: "ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION",
"ABLE LABORATORIES REPORTS SECOND QUARTER 2004 RESULTS NET SALES INCREASE 21% TO $23.0 MILLION FROM $18.9 MILLION FOR SECOND QUARTER OF 2003 SECOND QUARTER DILUTED EARNINGS PER SHARE OF $0.11 INCLUDES $810,000 OF NEW FACILITY AND ONE-TIME EXPENSES OPERATING INCOME OF $3.7 MILLION R&D EXPENSES OF $3.5 MILLION, AN INCREASE OF 53% VERSUS SECOND QUARTER 2003"
04/28/2004 8-K Quarterly results
Docs: "ITEM 9. REGULATION FD DISCLOSURE",
"ABLE LABORATORIES APPOINTS GARTH BOEHM PH.D. SENIOR VICE PRESIDENT AND CHIEF SCIENTIFIC OFFICER",
"ABLE LABORATORIES ANNOUNCES APPOINTMENT OF ROBERT J. MAURO PRESIDENT AND CHIEF OPERATING OFFICER",
"ABLE LABORATORIES REPORTS FIRST QUARTER 2004 RESULTS NET SALES INCREASE 43% TO $21.5 MILLION FROM $15.0 MILLION FOR FIRST QUARTER OF 2003 OPERATING INCOME, INCLUDING EFFECT OF 67% INCREASE IN R&D, INCREASES 49% TO $3.0 MILLION FIRST QUARTER DILUTED EARNINGS PER SHARE OF $0.10 INCLUDES $400,000 OF EXPENSES RELATED TO NEW FACILITY"
02/26/2004 8-K Results of Operations and Financial Condition
Docs: "ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION",
"ABLE LABORATORIES REPORTS RECORD SALES AND OPERATING INCOME FOR 2003 NET SALES $77.6 MILLION FOR 2003 VERSUS $52.9 MILLION FOR 2002 OPERATING INCOME $14.3 MILLION FOR 2003 VERSUS $10.9 MILLION FOR 2002 RESEARCH & DEVELOPMENT EXPENSES INCREASE TO $11.2 MILLION FOR 2003 DILUTED EARNINGS PER SHARE $0.46 FOR FULL YEAR, $0.13 FOR FOURTH QUARTER INCLUDES $300,000 Q4 2003 EXPENSES RELATED TO NEW FACILITY"
11/19/2003 8-K Financial statements and exhibits, Regulation FD Disclosure
Docs: "ITEM 9. REGULATION FD DISCLOSURE",
"ABLE LABORATORIES ANNOUNCES ACQUISITION OF LIQUISOURCE, INC."
11/04/2003 8-K Quarterly results
Docs: "ABLE LABORATORIES REPORTS THIRD QUARTER 2003 RESULTS"
07/28/2003 8-K Financial statements and exhibits, Regulation FD Disclosure
Docs: "ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS",
"ABLE LABORATORIES REPORTS RECORD SECOND QUARTER 2003 RESULTS"
06/30/2003 8-K Other events, Financial statements and exhibits
Docs: "ITEM 5. OTHER EVENTS",
"Form of Additional Investment Right",
"Securities Purchase Agreement among Able Laboratories, Inc. and the purchasers identified on the signature pages thereof",
"ABLE LABORATORIES ANNOUNCES $30.4 MILLION PRIVATE PLACEMENT OF COMMON STOCK"
06/18/2003 8-K Financial statements and exhibits, Regulation FD Disclosure
Docs: "ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS",
"Able Laboratories Announces Conversion of $2,150,000 of Debt"
05/06/2003 8-K Financial statements and exhibits, Regulation FD Disclosure
Docs: "ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS.",
"ABLE LABORATORIES REPORTS FIRST QUARTER 2003 RESULTS"
04/15/2003 8-K Financial statements and exhibits, Regulation FD Disclosure
Docs: "ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS.",
"Second Amendment to Credit Agreement",
"Amended and Restated Revolving Credit Note ITEM 9. REGULATION FD DISCLOSURE. Amendment to Secured Line of Credit On April 10, 2003, Able Laboratories, Inc. ("Able"), amended its line of credit with Citizens Bank of Massachusetts. Able established a certain non-restoring equipment loan facility in the maximum principal amount of $4,000,000 on October 24, 2002. On February 21, 2003, the non-restoring equipment loan facility was increased to an amount up to $5,800,000, and Able established a revolving line of credit facility (the "Revolving Credit Facility") in the maximum principal amount of up to $4,000,000 for working capital needs pursuant to, among other things, a First Amendment to Credit Agreement dated February 21, 2003. On April 10, 2003, Able increased the Revolving Credit Facility ..."
02/25/2003 8-K Other events, Financial statements and exhibits
Docs: "ITEM 5. OTHER EVENTS",
"ABLE LABORATORIES COMPLETES ADDITIONAL DEBT FINANCING OF $5.7 MILLION WITH CITIZENS BANK"
01/17/2003 8-K Other events, Financial statements and exhibits
Docs: "ITEM 5. OTHER EVENTS",
"ABLE LABORATORIES CONDUCTS LIMITED RECALL OF CARISOPRODOL TABLETS, USP 350 MG PER FDA GUIDELINES"
08/31/2001 8-K Other events, Financial statements and exhibits
Docs: "ITEM 5. OTHER EVENTS.",
"Certificate of Designations, Preferences and Rights of Series Q Convertible Preferred Stock as filed on August 15, 2001",
"Stock Purchase Agreement",
"Registration Rights Agreement",
"Description of Capital Stock",
"Able Laboratories Completes $6 Million Private Placement"
05/24/2001 8-K Other events, Financial statements and exhibits
Docs: "ITEM 5. OTHER EVENTS.",
"Certificate of Ownership and Merger",
"DYNAGEN, INC. CHANGES NAME TO ABLE LABORATORIES, INC."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy